Study number 779857
Dates
Apr 21 2026-Jul 01 2026
Location
Daytona Beach, Florida
Age
18-65
Gender
Male and Female
Smoker
Yes
Compensation
$12,049
Group
C2
This is a research study for a drug approved by the U.S Food and Drug Administration (FDA) for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. This study drug is also being developed for the potential treatment of autoimmune diseases, conditions in which the immune system mistakenly attacks the body.
Daytona Beach, FL is currently recruiting Healthy Adults, ages 18-65.
Refer a friend & receive $350 per qualified referral
Women Eligibility Criteria
Smoking Criteria
Body Mass Index
Screening procedures
Call now to schedule your screening appointment!
Cohort 2:
Check-in: April 21
Check-out: April 22
Follow-up visits: April 24, 29, May 2, 6, 13, 20, Jun 3, 17, Jul 1
Phone calls: May 27, Jun 10, 24